Loading...
XASX
AVE
Market cap45mUSD
Jul 10, Last price  
0.02AUD
1D
0.00%
1Q
144.44%
Jan 2017
-22.32%
Name

Avecho Biotechnology Ltd

Chart & Performance

D1W1MN
XASX:AVE chart
P/E
—
P/S
52.74
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.47%
Rev. gr., 5y
26.33%
Revenues
1m
+9.25%
1,379,0001,586,0001,693,000670,0004,660,0002,516,0001,530,0001,376,0002,053,0002,190,0001,588,0001,150,0001,252,0004,238,000384,627793,6001,129,000473,5511,133,0001,237,762
Net income
-4m
L+41.47%
-6,125,000-8,844,000-91,206,000-8,501,000-11,275,0001,106,000-11,055,000-12,673,000-8,935,000-20,120,000-17,314,000-8,618,000-3,991,000849,955-2,635,000-3,416,000-2,342,000-3,437,000-3,122,000-4,416,623
CFO
1m
P
-8,115,000-10,858,000-7,232,000-8,963,000-8,340,000-9,293,000-11,663,000-8,578,000-6,739,000-8,705,000-6,412,563-6,420,962-2,187,4711,188,808-1,423,167-3,098,674-1,665,207-3,179,955-3,968,7181,103,098
Dividend
May 19, 19970.02 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
URL
https://avecho.com.au/
IPO date
Aug 09, 1993
Employees
29
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT